Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Pharming Group has received a fast track designation on recombinant human C1 inhibitor, or rhC1INH, for the treatment of hereditary angioedema from the FDA.
Subscribe to our email newsletter
The fast track designation will provide an expedited review process rhC1INH. It also allows for more frequent interactions with the FDA, which could improve the efficiency of product development and decrease the typical review period.
There is no approved therapy available to hereditary angioedema (HAE) patients in the US for the treatment of acute attacks. Clinical studies of rhC1INH have shown that treatment with Pharming’s treatment candidate leads to rapid time to beginning of relief from the attack and reduces time to complete resolution.
The rhC1INH product has already been granted orphan drug status in this indication, which provides a seven-year period of market exclusivity in the US upon product approval.